Last reviewed · How we verify
NCT07125014
Frequency and Predictors of Post-ERCP Pancreatitis in a South Asian Tertiary Care Center
trial testing Observational study in Post-ERCP Pancreatitis in 300 participants. Completed in 31 December 2023.
14 December 2023
Quick facts
| Lead sponsor | Nangarhar University |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 300 |
| Start date | 1 January 2023 |
| Primary completion | 14 December 2023 |
| Estimated completion | 31 December 2023 |
| Sites | 1 location across Pakistan |
Drugs / interventions tested
- Observational study — full drug profile →
Conditions studied
- Post-ERCP Pancreatitis — all drugs for Post-ERCP Pancreatitis →
Sponsor
Nangarhar University
Who can join
18 and older, any sex, with Post-ERCP Pancreatitis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study was conducted at the Department of Gastroenterology, Lady Reading Hospital, Peshawar, Pakistan, from January 2023 to December 2023. It aimed to determine how often patients develop pancreatitis (inflammation of the pancreas) after undergoing a procedure called endoscopic retrograde cholangiopancreatography (ERCP), and to identify the main factors that increase this risk. We reviewed the medical records of 300 adult patients who had ERCP for various conditions, such as bile duct stones, tumors, and strictures. We assessed patient characteristics, procedure details, and laboratory results to see which factors were linked to post-ERCP pancreatitis. The study found that prolonged cannulation time, injection of contrast into the pancreatic duct, and high levels of C-reactive protein before the procedure were the strongest predictors of this complication. These findings may help doctors identify high-risk patients and take preventive steps to reduce the chances of pancreatitis after ERCP.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT07125014
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Observational study
Trials testing the same drug.
- NCT07255443 — Intestinal Colonization With Carbapenem Resistant Enterobacteriaceae Among ICU Patients at Assiut University Hospital · not yet recruiting
- NCT07343713 — Correlation Between the Degree of Middle Ear Pressure and the Eustachian Tube Dimensions : Radiological Study · not yet recruiting
- NCT07192991 — Neuroendocrine Carcinomas: Patient Journey And Treatment Outcomes In Latin America · not yet recruiting
- NCT07219927 — Real-World Patient Experiences Using Continuous Subcutaneous Apomorphine Infusion (ONAPGOTM) in the United States: · recruiting
- NCT06244238 — A Study on the Relationship Between Job Satisfaction and Retention Intentions of Emergency Room Nurses · unknown
Other recruiting trials for Post-ERCP Pancreatitis
Currently open trials in the same condition.
- NCT07088757 — Low-Dose vs Standard-Dose Indomethacin for Preventing Post-ERCP Pancreatitis · Phase 4 · recruiting
- NCT06250803 — Early Pancreatic Stent Placement for Preventing PEP · NA · recruiting
Other Nangarhar University trials
Trials by the same sponsor.
- NCT07126184 — Incidence and Predictors of Recurrent Stroke in Cryptogenic Stroke Patients With Atrial Fibrillation · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07125014 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Nangarhar University
- Last refreshed: 15 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07125014.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing